{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ibrahim SL"],"funding":["Iraqi Cultural Attaché in London (Iraqi Cultural Attaché - London)","North Staffordshire medical institute, Staffordshire No grant reference number.","Iraqi Cultural Attaché in London","Higher Committee for Education Development in Iraq (HCED)","Higher Committee for Education Development in Iraq"],"pagination":["896-906"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9977917"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["128(5)"],"pubmed_abstract":["<h4>Context</h4>Many cancer patients who initially respond to chemotherapy eventually develop chemoresistance, and to address this, we previously conducted a RNAi screen to identify genes contributing to resistance. One of the hits from the screen was branched-chain α-keto acid dehydrogenase kinase (BCKDK). BCKDK controls the metabolism of branched-chain amino acids (BCAAs) through phosphorylation and inactivation of the branched-chain α-keto acid dehydrogenase complex (BCKDH), thereby inhibiting catabolism of BCAAs.<h4>Methods</h4>We measured the impact on paclitaxel sensitivity of inhibiting BCKDK in ovarian and breast cancer cell lines.<h4>Results</h4>Inhibition of BCKDK using siRNA or two chemical inhibitors (BCKDKi) was synergistic with paclitaxel in both breast and ovarian cancer cel"],"journal":["British journal of cancer"],"pubmed_title":["Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel."],"pmcid":["PMC9977917"],"funding_grant_id":["D-11-296","S939","S1442"],"pubmed_authors":["Richardson A","Ibrahim SL","Price JC","Abdullah MI","Abed MN","Mohamed G"],"additional_accession":[]},"is_claimable":false,"name":"Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel.","description":"<h4>Context</h4>Many cancer patients who initially respond to chemotherapy eventually develop chemoresistance, and to address this, we previously conducted a RNAi screen to identify genes contributing to resistance. One of the hits from the screen was branched-chain α-keto acid dehydrogenase kinase (BCKDK). BCKDK controls the metabolism of branched-chain amino acids (BCAAs) through phosphorylation and inactivation of the branched-chain α-keto acid dehydrogenase complex (BCKDH), thereby inhibiting catabolism of BCAAs.<h4>Methods</h4>We measured the impact on paclitaxel sensitivity of inhibiting BCKDK in ovarian and breast cancer cell lines.<h4>Results</h4>Inhibition of BCKDK using siRNA or two chemical inhibitors (BCKDKi) was synergistic with paclitaxel in both breast and ovarian cancer cel","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2025-04-18T14:13:24.765Z","creation":"2025-04-07T00:15:00.574Z"},"accession":"S-EPMC9977917","cross_references":{"pubmed":["36526674"],"doi":["10.1038/s41416-022-02095-9"]}}